New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho)) - solution for injection - 10000 iu/ml - active: epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 16.8 µg/ml (human recombinant erythropoietin(r-huepo cho)) - solution for injection - 2000 iu/ml - active: epoetin alfa 16.8 µg/ml (human recombinant erythropoietin(r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 336 µg/ml (human recombinant erythropoietin) - solution for injection - 40000 iu/ml - active: epoetin alfa 336 µg/ml (human recombinant erythropoietin) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 33.6 µg/ml (human recombinant erythropoietin(r-huepo cho)) - solution for injection - 4000 iu/ml - active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin(r-huepo cho)) excipient: dibasic sodium phosphate dihydrate glycine monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection - eprex is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis. · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis. · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy. · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho));  ; epoetin alfa 84 µg/ml; epoetin alfa 84 µg/ml - solution for injection - 10000 iu/ml - active: epoetin alfa 84 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate glycine metacresol monobasic sodium phosphate dihydrate polysorbate 80 water for injection active: epoetin alfa 84 µg/ml excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection active: epoetin alfa 84 µg/ml excipient: albumin monobasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 168 µg/ml (human recombinant erythropoietin (r-huepo cho));   - solution for injection - 20000 iu/ml - active: epoetin alfa 168 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate glycine metacresol monobasic sodium phosphate dihydrate polysorbate 80 water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 16.8 µg/ml (human recombinant erythropoietin (r-huepo cho));  ; epoetin alfa 16.8 µg/ml - solution for injection - 2000 iu/ml - active: epoetin alfa 16.8 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection active: epoetin alfa 16.8 µg/ml excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho));  ; epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho)); epoetin alfa 33.6 µg/ml - solution for injection - 4000 iu/ml - active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho))   excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection active: epoetin alfa 33.6 µg/ml (human recombinant erythropoietin (r-huepo cho)) excipient: albumin dibasic sodium phosphate dihydrate glycine metacresol monobasic sodium phosphate dihydrate water for injection active: epoetin alfa 33.6 µg/ml excipient: albumin dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water

European Union - English - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).,

United States - English - NLM (National Library of Medicine)

amgen inc - darbepoetin alfa (unii: 15uq94pt4p) (darbepoetin alfa - unii:15uq94pt4p) - darbepoetin alfa 10 ug in 0.4 ml - aranesp is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and patients not on dialysis. aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. aranesp has not been shown to improve quality of life, fatigue, or patient well-being. aranesp is not indicated for use: •       in patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. •       in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. •       in patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. •       as a substitute for rbc transfusions in patients who require immediate correction o